If you follow supplement trends, you’ve probably noticed three ingredients popping up everywhere in 2026. Ashwagandha’s moved beyond the yoga crowd into mainstream stress relief. Colostrum is showing up in beauty products with price tags that’d make a luxury serum blush. And creatine - that familiar gym-bag staple - is suddenly being pitched as a brain supplement, a longevity hack, and a gummy candy, all at once.
Sounds like supplement industry business as usual, right? Well, not exactly - because these three aren’t on the same playing field when it comes to actual evidence, and the differences are bigger than most people realize.
Nutritional Outlook’s 2026 “Ingredients to Watch” report, built on SPINS market data, shows all three are driving serious growth. Ashwagandha sales hit $176 million across multi-outlet channels, up 27%. Colostrum’s beauty category exploded 2,454% - yes, that’s not a typo, and yes, the base was small, but still. Creatine surged 71.9% in performance, and gummy products alone jumped 360% year-on-year (SPINS State of Industries, March 2025).
So what’s actually backed by data and what’s getting ahead of itself? One of these three has solid clinical backing for its main use. One has a real safety question that hasn’t been fully resolved - and probably won’t be soon. And one is growing faster than the science can keep up, by a lot.
This isn’t a “take this, not that” piece. It’s a look at what the data actually says - and where the gaps are wide enough that they should influence what you buy, or whether you buy at all.
Ashwagandha: Good Stress Data, Real Safety Signal#
Ashwagandha is the one ingredient here with genuine traditional roots - centuries of use in Ayurvedic medicine as an adaptogen for stress, energy, and vitality. And here’s the thing that doesn’t happen often: the modern evidence actually lines up reasonably well with the tradition.
A 2024 systematic review and meta-analysis published in Explore looked at 9 randomized controlled trials with 558 participants (PubMed 39348746). The numbers are solid. Significant reductions in Perceived Stress Scale scores (mean difference -4.72), Hamilton Anxiety Scale scores (mean difference -2.19), and serum cortisol (mean difference -2.58). These aren’t tiny, barely-significant effects - they held across multiple studies. Most trials used 300-600 mg per day of standardized root extract, with benefits appearing around that 6-10 week mark.
NCCIH, the NIH’s complementary health arm - and a source that’s famously stingy with endorsements - acknowledges that “some clinical studies suggest” benefit for stress and sleep. For a conservative government institution, that’s basically a nod of approval.
So far, so good. But ashwagandha also comes with what might be 2026’s most interesting safety story, and it’s one of those situations where two things that seem to contradict each other can both be true.
On one side: a 12-month observational study of KSM-66 ashwagandha at 600 mg/day in 191 healthy adults found no serious adverse events. Liver, kidney, and thyroid parameters all stayed normal (Phytotherapy Research, 2026). The study was funded by Ixoreal Biomed, the manufacturer of KSM-66 - valid data, but worth knowing where the money came from. That’s the longest safety data we have, and the results are genuinely reassuring.
On the other side: a 2026 review of ashwagandha-associated liver injury cases documented a pattern you can’t just wave away. The majority involved hepatocellular injury. Most cases resolved after stopping the supplement. But several required transplantation, and there were deaths (HCA Healthcare, 2026). Rare events, yes. The incidence appears low. But they’re not imaginary, and someone who tells you otherwise isn’t being straight with you.
How can both be true? The liver injury signal might be rare and idiosyncratic - or it might be connected to specific formulations. Leaf extracts, multi-ingredient blends, products with adulterants rather than standardized root-only extracts like KSM-66. And here’s the consumer problem: most people can’t tell the difference, because many products don’t specify which part of the plant they use. Root-only standardized extracts - KSM-66, Sensoril, Shoden - have the best safety data behind them. Products using leaf or unspecified parts carry less-clear risk profiles. It’s the kind of detail that sounds like inside baseball but actually matters if you’re buying this stuff.
Beyond liver: NCCIH is explicit about other cautions, and these are less ambiguous. Ashwagandha is contraindicated during pregnancy - miscarriage risk is the specific concern cited. Safety during breastfeeding is unknown. People with thyroid conditions, autoimmune diseases (lupus, MS, rheumatoid arthritis), or upcoming surgery should consult a healthcare provider before using it. It may interact with sedatives, thyroid medications, blood pressure drugs, and diabetes medications. That’s not a short list.
The bottom line for ashwagandha: the stress and anxiety evidence is genuinely among the best you’ll find for any herbal supplement. I’d put it up against most things in that category. The safety picture isn’t a crisis - most people don’t experience problems - but it’s also not nothing, and the gap between “most people are fine” and “rare cases are severe” is exactly where you want to pay attention. If you choose to use it, standardized root extract with third-party testing is the safer path.
Colostrum: 2,454% Growth, Zero Beauty RCTs#
Colostrum represents 2026’s widest evidence-to-hype gap. And it’s not close.
Let’s start with what’s happening in the market, because the numbers are the story. SPINS data shows bovine colostrum supplements grew 2,454% in the beauty category - again, not a typo, and yes, the percentage gets inflated when you’re starting from a small base - along with 203% growth in natural immune. These are the kinds of numbers that make every supplement company’s product team sit up straight. Products are showing up in sleek packaging at premium price points, positioned as anti-aging, skin-rejuvenating, hair-strengthening solutions.
What’s actually in colostrum that makes these claims sound plausible? Immunoglobulins - especially IgG1 - lactoferrin, growth factors including EGF, TGF, and IGF-1, plus hyaluronic acid. These bioactive components are 100 to 1,000 times more concentrated than in mature milk. On a mechanistic level, you can absolutely see why someone would look at this and say “this should be good for skin.” Growth factors and hyaluronic acid are both used in evidence-backed topical skincare. Bovine colostrum contains them naturally. The logic is clean.
But mechanism is not clinical evidence, and this is where the gap opens up wide enough to drive a truck through.
A 2021 systematic review covering 28 papers across athletes, pediatric patients, ICU patients, and elderly populations found the strongest human data was for immune support - reduced upper respiratory infection incidence and duration in athletes - and gut barrier integrity during physiological stress (Nutrients, 2021; PMC8308243). A 2024 crossover RCT in 28 endurance athletes using 25g/day found significant increases in post-exercise salivary SIgA, a key immune marker (Frontiers in Immunology, 2024).
That’s real, legitimate evidence. For immune and gut support in active people. But - and this is the entire point - none of it is for skin aging, hair growth, nail strength, or any beauty outcome. Zero. The 2,454% beauty growth is built almost entirely on mechanistic reasoning - “colostrum contains compounds relevant to skin” - rather than on direct clinical trials showing that taking it orally improves skin appearance, reduces wrinkles, or does anything cosmetic. If you’re buying colostrum for immune or gut support, there’s data behind that decision. If you’re buying it for beauty, you’re in evidence-free territory. Not “weak evidence.” Not “early evidence.” Evidence-free.
There’s another wrinkle worth mentioning: the dosing is all over the map. Clinical studies use anywhere from 1 gram to 60 grams per day - a sixty-fold range. Most consumer supplements clock in at 500 mg to 2 grams per serving, which is well below the doses used in most positive studies. So even in the areas where evidence exists, what’s on the shelf might not match what was studied.
Safety-wise, the lines are clearer. Bovine colostrum is contraindicated for people with cow’s milk allergy - that one’s firm. The lactose question is genuinely contested: some medical sources say colostrum is low-lactose enough to be tolerated, others say caution is warranted. GI side effects (nausea, bloating, diarrhea) are dose-dependent, which isn’t surprising for a dairy-derived product. There’s insufficient safety data for pregnancy and breastfeeding, so the prudent move is avoidance or a direct conversation with your doctor. One fear that can be put to rest: despite containing IGF-1 growth factors, studies confirm oral colostrum does not elevate circulating IGF-1 levels. The theoretical cancer or hormonal concern hasn’t materialized in blood work.
The colostrum story, if you squint at it honestly, is that there’s a solid supplement hiding inside a marketing narrative that’s outrun the science by a wide margin. The immune and gut evidence is worth paying attention to - especially for athletes and active people. But if your interest is beauty and skin aging, the bottle is promising something the data can’t deliver yet. That might be fine for some people - there’s nothing wrong with buying a bet on mechanism if you know that’s what you’re doing - but it’s worth knowing the bet you’re actually placing.
Creatine: The Best Evidence, The Most Noise#
Creatine is the strangest case of the three. It has the strongest evidence - decades of it - and somehow also the most persistent myths and the newest unproven claims, all circulating at once.
The muscle and performance evidence is about as close to settled science as supplement research gets. Creatine monohydrate at 3-5 grams per day reliably increases muscle strength and power output in resistance training. The phosphocreatine system - replenishing ATP during high-energy demand - is well understood. There’s no real debate at this point, and there hasn’t been for a while.
What’s new in 2026 is the cognitive angle, and it deserves a more careful look than the marketing copy usually gives it. A 2024 meta-analysis of 16 RCTs with 492 participants found creatine improved memory with moderate-certainty evidence (SMD = 0.31, GRADE: moderate) and processing speed (SMD = -0.51, though evidence certainty for this outcome was lower), with stronger effects in women and clinical populations (Frontiers in Nutrition, 2024; PMC11275561). These are real findings. They’re also modest - not “creatine makes you smarter,” not “creatine replaces your morning coffee,” just a measurable improvement in specific cognitive domains at a level that probably doesn’t feel dramatic in daily life. Executive function and global cognition measures didn’t show significant improvement. And the optimal dose for brain benefits versus muscle benefits isn’t settled. Some researchers suggest it might take higher amounts than the standard 5g/day, but that’s hypothesis, not established fact.
Then there’s the gummy situation, which is its own special kind of mess. Creatine gummy products exploded 360% year-on-year per SPINS. They’re everywhere - brightly colored, candy-adjacent, pitched as convenient and lifestyle-friendly. The problem: roughly half of them fail label claims. NutraIngredients reported in January 2026 that about 50% of tested creatine gummies don’t meet their stated content because creatine degrades into creatinine - a breakdown product with no ergogenic benefit - when exposed to heat, moisture, and acidic environments. And here’s the thing: fruity gummy formulations create exactly those conditions. Consumers paying premium prices for gummy convenience may literally be getting half the creatine they paid for. Creatine monohydrate powder, by contrast, is stable, dirt-simple, well-studied, and typically costs less.
One more thing worth addressing because it refuses to die: the kidney myth. A 2025 safety review in Frontiers in Nutrition concluded that concerns about creatine harming kidney function in healthy people are unsupported - Grade I evidence, the highest certainty level in their framework. Creatine supplementation raises serum creatinine, yes - but creatinine is literally a creatine breakdown product. That rise is a normal metabolic effect, not a sign of kidney damage. If you’ve heard someone say “creatine will wreck your kidneys,” they’re repeating a myth that’s been debunked by multiple systematic reviews. For people with pre-existing kidney disease, the advice is different: consult a doctor and use alternative kidney function markers like cystatin C rather than creatinine.
And while we’re on the subject of who should be careful: pregnancy. Animal studies have shown neuroprotective effects from creatine supplementation, but there are no human RCTs in pregnancy - zero. Creatine isn’t currently recommended for use during pregnancy outside of research settings. If you’re pregnant or planning to be, this falls squarely in the “talk to your doctor, not a product page” category.
A few other practical notes, since people always ask: the 1-2 kg weight gain is normal and is intracellular water stored alongside creatine in muscle - not bloating, not fat. GI distress is possible above 5 grams in a single dose; splitting doses usually takes care of it. Vegetarians and vegans tend to respond more strongly because their baseline creatine stores are lower - no dietary creatine from meat. And some people are just non-responders who don’t see benefits for reasons nobody fully understands yet.
Creatine’s evidence-to-hype gap isn’t about the ingredient being ineffective. It’s genuinely effective for its core uses - that’s not in question. The gap is between the careful, modest cognitive findings coming out of the research literature and the broader “creatine for your brain” wellness narrative that’s running ahead of the data. And the gap between a reliable tub of powder and a bag of gummies that might - coin flip - contain what it says on the label.
How to Think About These Three in 2026#
If you’re trying to navigate this landscape as a consumer, the practical version breaks down something like this.
Ashwagandha has real evidence for stress and anxiety reduction, backed by multiple RCTs and a meta-analysis. It also has a rare but documented liver safety signal, a clear pregnancy contraindication, and caution flags for thyroid conditions, autoimmune disease, and multiple drug classes. The smart move: standardized root extract - not leaf, not unspecified part - with third-party testing, and a conversation with your doctor if any of those flagged conditions apply to you.
Colostrum has meaningful evidence for immune and gut support, particularly in athletes and active people. If that’s why you’re interested, the data supports your interest. For beauty, skin aging, and hair claims - the ones driving the explosive growth - the clinical evidence simply isn’t there. You’re paying for mechanism and hope. Knowing that might change whether you buy it, or it might not, but there’s value in knowing what kind of bet you’re placing.
Creatine has the best evidence of the three, full stop. The muscle benefits are settled. The cognitive data is emerging and real but modest - not a brain transplant, not a nootropic revolution, just a measurable improvement in specific memory and processing-speed domains. If you choose creatine, monohydrate powder from a third-party tested brand is the best-studied, most reliable, and typically cheapest option. If you choose gummies, understand that you’re paying more for a product that, about half the time, doesn’t deliver what the label says. That’s not speculation - that’s what testing found.
None of these three are scams. All of them have legitimate reasons to be popular. But popularity and marketing have a way of getting ahead of the evidence, and the distance between the two is different for each one. Knowing that distance - roughly where the evidence stops and the claims keeping going - is the difference between an informed choice and a bet on the label copy.
One last thing, and it’s the one supplement articles tend to bury in a single sentence at the end: talk to a qualified health professional before starting any new supplement, particularly if you’re pregnant, breastfeeding, managing a chronic condition, or taking medications. These three ingredients all have interactions and cautions that deserve professional attention. Not a web search. Not a well-written product page. A conversation with someone who knows your full health picture. That’s not boilerplate - it’s the part that actually matters if something goes wrong.
